Canary Bio Presents at International Gynecologic Oncology Society Meeting

[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 5th that it will present the Phase 2 clinical trial results and the progress of the global Phase 3 clinical trial of the ovarian cancer treatment Oregovomab at the 2022 International Gynecologic Cancer Society (IGCS) Annual Global Meeting 2022, held in New York, USA, from September 29 to October 1.

Additionally, at this conference, Professor Lee Jung-yoon of Yonsei University Severance Hospital, who is conducting investigator-initiated clinical trials targeting recurrent ovarian cancer patients with Oregovomab, will also give a separate presentation.

Given that this presentation is taking place at the internationally renowned IGCS conference in the field of gynecologic oncology, it is expected that interest from related industries will increase further.

Oregovomab is a new drug that showed encouraging results in the Phase 2 clinical trial for ovarian cancer patients, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months. The p-value for overall survival (OS) was 0.0043, and the p-value for progression-free survival (PFS) was 0.0027. It was also recommended as the most promising immuno-oncology drug targeting ovarian cancer on the oncology specialist site 'OncoLive.'

Meanwhile, based on the Phase 2 clinical trial results, the global Phase 3 clinical trial of Oregovomab is recruiting patients at 152 sites across 16 countries. Recently, clinical sites were added in India, and patient recruitment has surpassed 60% of the target enrollment (a total of 602 patients).

This content was produced with the assistance of AI translation services.